Treatment of venous thromboembolism

Thrombosis Research

Volumn 97, Issue 1, 2000, Pages

  Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Home treatment; Low molecular weight heparin; Unfractionated heparin; Venous thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SECONDARY PREVENTION; THROMBECTOMY; THROMBOEMBOLISM; VEIN THROMBOSIS; VENA CAVA FILTER;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HEPARIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0033985977     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00193-0     Document Type: Article

References (51)

1. Kearon C. Initial treatment of venous thromboembolism. Thromb Haemost. 82(2):1999;887-891.
2. Goldhaber S.Z., Visani L., De Rosa M., for ICOPER Acute pulmonary embolism. Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) Lancet. 353:1999;1386-1389.
3. Prandoni P., Lensing A.W.A., Cogo A., Cuppini S., Villalta S., Carta M., Cattelan A.M., Polistena P., Bernardi E., Prins M.H. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 125:1996;1-7.
4. Hirsh J. Drug therapy. Heparin. N Engl J Med. 324:1991;1565-1574.
5. Hyers T.M., Agnelli G., Hull R., Weg J.G., Morris T.A., Samama M., Tapson V. Antithrombotic therapy for venous thromboembolic disease. Chest. 114:1998;561S-578S.
6. Brandjes D.P.M., Heijboer H., Büller H.R., de Rijk M., Jagt H., ten Cate J.W. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med. 327:1992;1485-1489.
7. Hirsh J., Dalen J.E., Anderson D.R., Deykin D., Poller L., Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 114:1998;445S-469S.
8. Cruickshank M.K., Levine M.N., Hirsh J., Roberts R.S., Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med. 151:1991;333-337.
9. Hirsh J., Warkentin T.E., Raschke R., Granger C.B., Ohman M., Dalen J.E. Heparin and low-molecular-weight heparin. Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 114:1998;489S-510S.
10. Pini M., Pattacini C., Quintavalla R., Poli T., Megha A., Tagliaferri A., Manotti C., Dettori A.G. Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis - A randomized clinical trial. Thromb Haemost. 64:1990;222-226.
11. Glimelius B., Busch C., Hook M. Binding of heparin on the surface of cultured endothelial cells. Thromb Res. 12:1978;73-82.
12. Hull R.D., Raskob G.E., Hirsh J., Jay R.M., Leclerc J.R., Geerts W.H., Rosenbloom D., Sackett D.L., Anderson C., Harrison L. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med. 315:1986;1109-1114.
13. Gallus A., Jackman J., Tillet J., Mills W., Sycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. II:1986;1293-1296.
14. Hull R.D., Raskob G.E., Rosembloom D., Panju A.A., Brill-Edwards P., Ginsberg J.S., Hirsh J., Martin G.J., Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 322:1990;1260-1264.
15. Bates S.M., Hirsh J. Treatment of venous thromboembolism. Thromb Haemost. 82(1):1999;870-877.
16. Young E., Cosmi B., Weitz J., Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin to plasma proteins. Thromb Haemost. 70:1993;625-630.
17. Young E., Prins M., Levine M.N., Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 67:1992;639-643.
18. Hirsh J., Levine M.N. Low molecular weight heparin. Blood. 79(1):1992;1-17.
19. Duroux P. A Collaborative European Study. a randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis Thromb Haemost. 65:1991;251-256.
20. Bratt G., Tornebohn E., Granqvist S., Aberg W., Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost. 54(4):1985;813-817.
21. Holm H.A., Ly B., Handeland G.F., Abildgaard U., Arnesen K.E., Gottschalck P. Subcutaneous heparin treatment of deep vein thrombosis. A comparison of unfractionated and low molecular weight heparin Haemostasis. 16:1986;30-37.
22. Lopaciuk S., Meissner A.J., Filipecki S., Zawilska K., Sowier J., Ciesielski L., Bielawiec M., Glowinski S., Czestochowska E. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis. A Polish multicenter trial Thromb Haemost. 68(1):1992;14-18.
23. Hull R.D., Raskob G.E., Pineo G.F., Green D., Trowbridge A.A., Elliot G., Lerner R.B., Hall J., Sparling T., Brettell H.R., Norton J., Carter C.J., George R., Merli G., Ward M., Mayo W., Rosenbloom D., Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med. 326:1992;975-982.
24. Prandoni P., Lensing A.W.A., Büller H.R., Carta M., Cogo A., Vigo M., Casara D., Ruol A., ten Cate J.W. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet. 339:1992;441-445.
25. Leizorovicz A., Simonneau G., Decousus H., Boissel J.P. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis. Meta-analysis BMJ. 309:1994;299-304.
26. Lensing A.W.A., Prins M.H., Davidson B.L., Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins. Arch Intern Med. 155:1995;601-607.
27. Siragusa S., Cosmi B., Piovella F., Hirsh J., Ginsberg J.S. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism. Results of a meta-analysis Am J Med. 100:1996;269-277.
28. Dolovich J., Ginsberg J. Low molecular weight heparins in the treatment of venous thromboembolism. Vessels. 3:1997;4-11.
29. The Columbus Investigators Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 337:1997;657-662.
30. Simonneau G., Sors H., Charbonnier B., for the THESEE Study Group A comparison of low molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 337:1997;663-669.
31. Hull R., Delmore T., Genton E., Hirsh J., Gent M., Sackett D., McLoughlin D., Armstrong P. Warfarin sodium versus low dose heparin in the long term treatment of venous thrombosis. N Engl J Med. 301:1979;855-858.
32. Koopman M.M.W., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P.M., van der Meer J., Gallus A.S., Simonneau G., Chesterman Ch Prins M.H., Bossuyt P.M.M., de Haes H., van den Belt A.G.M., Sagnard L., d'Azemar P., Buller H.R. Treatment of venous thrombosis with intravenous unfractionated heparin administered in hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med. 334:1996;682-687.
33. Levine M., Gent M., Hirsh J., Leclerc J., Anderson D., Weitz J., Ginsberg J., Turpie A.G., Demers C., Kovacs M., Geerts W., Kassis J., Desjardins L., Cusson J., Cruickshank M., Powers P., Brien W., Haley S., Willan A. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 334:1996;677-681.
34. Wells P.S., Kovacs M.J., Bormanis J., Forgie M.A., Goudie D., Morrow B., Kovacs J. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin. Arch Intern Med. 158:1998;1809-1812.
35. Harrison L., McGinnis J., Crowther M., Ginsberg J., Hirsh J. Assessment of outpatient treatment of deep vein thrombosis with low molecular weight heparin. Arch Intern Med. 158:1998;2001-2003.
36. Jerjes-Sanchez C., Ramirez-Rivera A., Garcia M.L., Arriaga-Nava R., Valencia S., Rosado Buzzo A. Streptokinase and heparin versus heparin alone in massive pulmonary embolism. A randomized controlled trial J Thromb Thrombolysis. 2:1995;227-229.
37. Lensing A.W.A., Hirsh J. Rationale and results of thrombolytic therapy for deep vein thrombosis. Bernstein E.F. Vascular Diagnosis. 4th ed:1993;875-879 Mosby, St. Louis.
38. Haire W.D. Vena caval filters for the prevention of pulmonary embolism. N Engl J Med. 338:1998;463-464.
39. Decousus H., Leizorovicz A., Parent F., Page Y., Tardy B., Girard P., Laporte S., Faivre R., Charbonnier B., Barral F.G., Huet Y., Simonneau G. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 338:1998;409-415.
40. Pacouret G., Alison D., Pottier J.M., Bertrand P., Charbonnier B. Free-floating thrombus and embolic risk in patients with angiographically confirmed proximal deep venous thrombosis. A prospective study. Arch Intern Med. 157:1997;305-308.
41. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 324:1991;1865-1875.
42. Harrison L., Johnston M., Massicotte P., Crowther M., Moffat K., Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 126:1997;133-136.
43. Crowther M.A., Ginsberg J.S., Kearon C., Harrison L., Johnson J., Massicotte M.P., Hirsh J. A randomized trial comparing 5 mg and 10 mg warfarin loading doses. Arch Intern Med. 159:1999;46-48.
44. Hull R.D., Hirsh J., Jay R., Carter J., England C., Gent M., Turpie A.G., McLoughlin D., Dodd P., Thomas M., Raskob G., Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med. 307:1982;1676-1681.
45. Coon W.W., Willis P.W. Recurrence of venous thromboembolism. Surgery. 73:1973;823-827.
46. Research Committee of the British Thoracic Society Optimal duration of anticoagulation for deep vein thrombosis and pulmonary embolism. Lancet. 340:1992;873-876.
47. Prandoni P., Lensing A.W.A., Büller H.R., Cogo A., Prins M.H., Cattelan A.M., Cuppini S., Noventa F., ten Cate J.W. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 327:1993;1128-1133.
48. Schulman S., Rhedin A.S., Lindmarker P., Carlsson A., Larfars G., Nicol P., Loogna E., Svensson E., Ljungberg B., Walter H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 332:1995;1661-1665.
49. Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M., Anderson D.R., Turpie A.G., Green D., Ginsberg J.S., Wells P., MacKinnon P., Julian J.A. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 340:1999;901-907.
50. Agnelli G., Prandoni P., Santamaria M.G., Bagatella P., Ascani A., Bazzan M., Alatri A., Guazzaloca G., Bertoldi A., Tomasi G., Scannapieco G., Ageno W., Iorio A. Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis. The Warfarin Optimal Duration Italian Trial (WODIT) Thromb Haemost. Suppl.):1999;2164.
51. Schulman S., Granqvist S., Holmström M., Carlsson A., Lindmarker P., Nicol P., Eklund S.G., Nordlander S., Larfars G., Leijd B., Linder O., Loogna E. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 336:1997;393-398.